---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-028157"
form_type: "8-K"
ticker: "PVCT"
cik: "0000315545"
company_name: "PROVECTUS BIOPHARMACEUTICALS, INC."
filed_at: "2024-07-17T23:59:59+00:00"
generated_at: "2026-05-31T20:18:31.113274+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Provectus announces up to $10M convertible loan financing at 8% interest

## Summary
- Board approved term sheet for up to $10M unsecured convertible loan (2024 Financing) from multiple investors.
- Loan bears 8% annual interest, matures in 12 months, convertible into Series D-1 Preferred at $2.8620/share.
- Series D-1 Preferred convertible into 10 shares of common stock per preferred share.
- Proceeds will fund drug discovery and development programs and G&A expenses.
- Also closed previously reported 2022 Financing totaling $4,865,500 as of July 11, 2024.

## SEC filing metadata
- accession: 0001493152-24-028157
- form_type: 8-K
- ticker: PVCT
- cik: 0000315545
- company_name: PROVECTUS BIOPHARMACEUTICALS, INC.
- filed_at: 2024-07-17T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/315545/000149315224028157/0001493152-24-028157-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/315545/000149315224028157/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-028157
- JSON: https://secwatch.observer/filing/0001493152-24-028157.json
- Plain text: https://secwatch.observer/filing/0001493152-24-028157.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.